Last updated: February 13, 2026
What is NDC 00002-1484?
NDC 00002-1484 corresponds to Dupixent (dupilumab), a monoclonal antibody developed by Sanofi and Regeneron. It is indicated for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Market Overview
Market Size
- Dupixent has achieved rapid growth in the biologics space due to broad indications.
- Estimated global sales reached approximately $8.5 billion in 2022, with the US accounting for over 70% of revenues.
- The global dermatology market, where Dupixent primarily competes, was valued at $21 billion in 2022.
Competitive Landscape
- Main competitors include Humira (adalimumab), Stelara (ustekinumab), and other biologics targeting similar inflammatory pathways.
- Dupixent's key advantages: subcutaneous administration, targeted mechanism, favorable safety profile.
- Patent protection extends into the late 2020s, with biosimilar competition anticipated post-2030.
Regulatory Status
- FDA approval date: March 2017.
- Expanded indications include eosinophilic esophagitis (April 2022), and pediatric use.
- Pending or approved filings in international markets. Japan, EU approvals came in 2018-2019.
Market Penetration and Adoption Trends
- Rapid adoption in dermatology and pulmonology markets.
- Current usage suggests a treatment prevalence rate of 4-6% among eligible patient populations.
- Estimated number of eligible US patients: 10 million for atopic dermatitis, with higher utilization driven by insurance coverage and clinician familiarity.
Price Dynamics
Current Pricing
- List price per injection: approximately $3,000.
- Dosing: every 2 weeks; typical annual cost ~ $39,000.
- Pricing reflects biologic manufacturing costs (~$1,000 per dose) and premium positioning.
Reimbursement and Payer Coverage
- High coverage rates in Medicare and private insurance.
- Patient assistance programs reduce out-of-pocket costs, influencing market penetration.
Price Projections (Next 5-10 Years)
| Year |
Projected Average Price |
Notes |
| 2023 |
$3,000 per injection |
Stable, with minor inflation adjustments (~3-5%) |
| 2025 |
$3,150 |
Expected inflation; potential biosimilar entry in late 2020s |
| 2027 |
$3,300 |
Biosimilar competition looms; price stabilization forecasted if biosimilars launch |
| 2030 |
$2,400-$2,800 |
Biosimilar availability expected; discounts may be applied to maintain market share |
Key assumptions behind projections:
- Market penetration maintains growth at 5-8% annually.
- Biosimilar entry reduces list prices by 30-50% but encourages further adoption.
- Reimbursement policies remain favorable; high payer coverage sustains demand.
- Patent exclusivity extends into 2028; biosimilar competition anticipated thereafter.
Potential Risks
- Accelerated biosimilar or generic competition.
- Regulatory changes influence pricing or market access.
- Shifts in clinical guidelines affecting treatment preferences.
- Patent litigation or patent cliff effects.
Key Takeaways
- Dupixent holds a dominant position within its target markets with sustained high sales.
- Pricing remains stable with expected inflation; biosimilars may significantly impact prices post-2028.
- Market expansion into new indications could boost revenue but faces uncertainties due to competitive pressures.
- The current average annual treatment cost is approximately $39,000, with potential decreases correlated with biosimilar market entry.
- Regulatory and reimbursement environments strongly influence pricing and market share trajectories.
FAQs
-
When is biosimilar competition expected for Dupixent?
Biosimilar entries could emerge post-2028, following patent expiry, potentially lowering prices significantly.
-
How does Dupixent compare price-wise with other biologics?
Dupixent's current list price is comparable to other monoclonal antibodies treating chronic inflammatory diseases, typically ranging between $2,500 and $4,000 per dose.
-
What factors influence future price declines?
Competition from biosimilars, patent expirations, and payer negotiations are primary drivers for price reductions.
-
What new indications are under development?
Additional uses include eosinophilic esophagitis and potential asthma-related pediatric labels, broadening the market.
-
How does market adoption impact price projections?
Higher penetration and broader indications increase revenue, supporting stable or slightly elevated prices until biosimilar competition intensifies.
References
[1] Sanofi and Regeneron Annual Reports, 2022.
[2] IQVIA Reports, 2022.
[3] U.S. Food and Drug Administration (FDA) Approval Letters, 2017; 2022.
[4] MarketWatch and Evaluate Pharma Data, 2022.
[5] Industry Analysis, “Biologics Market Trends,” PwC, 2021.
